The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Shpunken, fully agree with you but I wouldn’t imagine the company will be sold until the Gas Exchange is approved.
When that is approved IMO we will be looking at £400m+ (50 x current valuation) if the company was sold.
I’m prepared to give CVJ the benefit of the doubt as I believe there are a lot of positive things happening in the background.
The 10 months he has had is not a lot of time considering the sector we are in. The next few months are huge for the company
I’m very much hoping he pulls a rabbit out of the hat with the funding and gets some momentum going with positive news.
I think he will!
With the deal that CVJ has signed up to, it is very much within his own interests (and the entire board) to have minimal dilution in the next fundraise.
It will be interesting to see what happens.
Fingers crossed for a good result!
Dr. von Jako was granted 5,325,000 stock options to participate in the Polarean Imaging plc Share Option Plan (the "Share Options"). 25% of the Share Options will vest on 20 June 2024 with the remaining Share Options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on July 31, 2024, subject to his continued employment with the Company and the exercise price shall be 29p per Share Option
👀👀👀
https://classic.clinicaltrials.gov/ct2/show/study/NCT04855305
This time next year Rodney!
U.S. Patent granted for dynamic cardiopulmonary blood flow imaging with Xenon MRI
New patent expands the utility of hyperpolarised Xenon MRI in the diagnosis and monitoring of diseases of the pulmonary vasculature
Great RNS - this is only going one way
Gas Exchange = $$$$$$$$$$$’ers
Agreed Big Slick, with the fund raise coming, im surprised we have not be on the weekly agenda for the likes of Investor Meet Company meetings or doing similar types of promotion.
Can only hope the management have bigger things going on in the background
Nice one JJ7.
Yes, i think you are right that the Gas Exchange approval could be expedited.
There are so many trials going on and all are proving the technology works in this space, I think approval in 2025 has got a real chance.
Thanks for this JJ7, fully agree with you.
I have seen comms from the company with regard to the Gas Exchange (which I would happily share with anybody). It is going to be game changing.
I notice on the Gas Exchnage Trial page the estimated end date has come into August 2026, not a huge amount of time in the grand scheme of things.
I like how animated CVJ gets on the Proactive update when he talks about Gas Exchange
https://youtu.be/cTmRMGlsKSo?si=3I8qTcT886Uf3nvH
No links JJ7 but the endorsement section of LinkedIn has a very interesting new European based company (I don’t think it’s appropriate to put the name on BB’s without evidence) but I did some research on the company last night and it looks a great match to what polx are trying to do.
Also the person doing the liking and their closest peers are all respiratory and imagining
One of them is a global monster very active in the respiratory space, they are also very involved in parterships and licensing and it’s not the AstraZeneca endorsement
In the last day there has been some very interesting new companies endorsing Polarean on their social media pages.
There seems to be things happening in Europe IMO.
Cluster analysis to identify long COVID phenotypes using 129Xe magnetic resonance imaging
Taken from the full PDF report - https://erj.ersjournals.com/content/erj/63/3/2302301.full.pdf
Long COVID impacts ∼10% of people diagnosed with coronavirus disease 2019 (COVID[1]19), yet the pathophysiology driving ongoing symptoms is poorly understood. We hypothesised that 129Xe magnetic resonance imaging (MRI) could identify unique pulmonary phenotypic subgroups of long COVID. Therefore, we evaluated…Ventilation… and…Gas Exchange…measurements with cluster analysis to generate imaging-based phenotypes.
Conclusions
In conclusion, we demonstrate four unique long COVID phenotypes defined by 129Xe MRI metrics, with distinct functional MRI and corresponding clinical characteristics. Such differences were otherwise…Not… evident in the total long COVID group compared with COVID-negative and fully recovered post-COVID participants,…Especially… using PFTs and CT. These four clusters reveal distinct ( patho-)physiological changes that can be potential targets for therapy. Although a relatively new technology, 129Xe MRI is now approved for clinical use in the UK and USA [31], providing new clinical opportunities for improved characterisation of respiratory diseases [38] and targeting of therapeutics for patients with long COVID.
Future work can build from this foundation towards personalised medicine to evaluate the biological underpinnings of 129Xe MRI signatures of long COVID clusters, and to determine their disease trajectories and responses to therapy
Nice!
couldn’t agree more big slick.
we need to get to break even asap. i feel conversion of the 15 research sites and a couple of new sites will get us there no problem.
that should fairly value the company at around £100m
then it’s on the gas exchange, get that approved and you can 5 times that valuation on the day.
i have done some research on what the current reimbursement is for the gas exchange equivalent and it is big $$$$.
polx will make a huge impact in this market as the current standard is appalling - 6 minute walks up and down hospital corridors with a stop watch etc!
we will be ****t1ng cash by 2030
im happy to pick up shares under 10p and stick them in the bottom drawer
loads to play for here.
gla
Agreed Big Slick more clarity would be good, but we won’t get it as it’s an Amati issue not a polarean issue.
The wording in the RNS leads me to believe it is not a conspiracy:
We are considering the Company's strategic options in the light of ongoing challenges in the AIM market and the resultant performance issues faced by the Company
the resultant performance issues faced by the Company says it all - no conspiracy there in my view
i would happily join your party john :)
however, i do feel for amati here, they have backed the company well but clearly there is something wrong structurally and financially and polx happen to be at the **** end off it dragging the sp down to 4p - ludicrous!
Thanks unhooked.
Jeez, I feel for them, looks like they will be out by the end of the day… another 1m odd gone through
On Cue, RNS from Amati this morning!
The last sentence,
‘and the resultant performance issues faced by the Company’. - Ouch
The Board of Amati AIM VCT plc (the "Company") confirms that it has, in conjunction with the Company's investment manager, Amati Global Investors Limited (the "Investment Manager"), been considering the Company's strategic options in the light of ongoing challenges in the AIM market and the resultant performance issues faced by the Company.
PS - Amphion had to sell because they went bust!
Amati are clearly not going to go bust but imo it makes zero financial sense to be selling to Nukem at 5p unless they need the money urgently!